Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis receives approval for new Afinitor breast cancer indication

Novartis receives approval for new Afinitor breast cancer indication

2nd August 2012

Novartis has been granted European regulatory approval for its oncology therapy Afinitor in a new indication.

The European Commission has approved the drug for use in combination with exemestane against hormone receptor-positive, HER2/neu-negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.

This is the most common form of advanced breast cancer, with Afinitor being the first mTOR inhibitor therapy to be approved for use against the disease.

Data from the phase III Bolero-2 trial demonstrated that the product can significantly improve survival rates among patients.

Herve Hoppenot, president at Novartis Oncology, said: "Treatment with Afinitor gives women a new option in the battle against this advanced form of breast cancer, where there remains a significant unmet need."

Last month, the company published its financial report for the second quarter of 2012, during which it experienced a one percent year-on-year growth in sales.ADNFCR-8000103-ID-801420550-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.